Slide 1: Annual General Meeting in CellaVision 2011
Annual General Meeting in CellaVision 2011 Yvonne Mårtensson, CEO
Slide 2: Introduction
Introduction CellaVision is world leader in a market with large potential, offering automated digital cell morphology The hematology analysis market comprises more than 1 billion CBC tests a year – manual differential work equivalent to more than USD 1 billion CellaVision’s market includes products
Slide 3: Global customer base
Global customer base 900 systems mainly in Europe and North America Hospital and commercial hematology laboratories The hospital demand for efficiency and cost reduction makes automation the obvious choice The labor shortage of biomedical scientists is a market driver 3
Slide 4: Our unique technology adds value
Our unique technology adds value Efficiency cost reduction and increased productivity Proficiency increased quality of results Connectivity between sites; enhanced opportunity for collaboration and sharing of competences 4
Slide 5: The analyses often constitute important reference data for diagnosis
The analyses often constitute important reference data for fast and correct diagnosis of illnesses Blood infections, allergies, anemia, and serious blood cancers such as leukemia and lymphoma Body fluids infections, inflammations, parasitic diseases and various cancers 5
Slide 6: 42 customers in the Nordic countries
42 customers in the Nordic countries Sweden Uppsala Karolinska Huddinge Norway Danderyd Trondheim Södersjukhuset Stavanger S:t Görans Nya Ahus Eskilstuna Linköping Skövde Iceland Jönköping Reykjavik Trollhättan Sahlgrenska Östra Sjukhuset Borås Varberg Denmark Halmstad Aalborg Växjö Aarhus Västervik
Slide 7: Network capabilities give staffing flexibility at Karolinska University Hospital
Network capabilities give staffing flexibility at Karolinska University Hospital, Stockholm Solna Danderyd Huddinge Södertälje Norrtälje Söder, Stockholm 7
Slide 8: CellaVision in short
CellaVision in short Sales through Sysmex and Beckman Coulter. Direct sales through subsidiaries in the Nordic countries, the US, Canada and Japan Headquarters in Lund, Sweden 58 employees Manufacturing outsourced to Kitron AB, Karlskoga, Sweden 18 patented innovations Competition: Manual microscopy
Slide 9: CellaVision's product offering
CellaVision’s product offering Analyzers CellaVision® DM96 CellaVision® DM1200 Optional application for body fluids analysis CellaVision® Body Fluid Application Software for networking and remote access CellaVision® Remote Review Software Software for proficiency testing and education CellaVision® C
Slide 10: Financial performance 2001–2010
Financial performance 2001–2010 10
Slide 11: Sales per geographical segment
Sales per geographical segment 11
Slide 12: Achievements in 2010
Achievements in 2010 Another year of profit and strong growth Net sales rose by 21 % to SEK 131.6 million (109.0). Operating profit for the year was SEK 13.9 million (14.8). Profit after tax was SEK 38.3 million (27.7) Earnings per share for the year were SEK 1.61 (1.16). Cash and cash equivalents a
Slide 13: Financial objectives
Financial objectives CellaVision's target is to increase sales by an average of at least 15 % per year over an economic cycle with an operating margin of more than 15 %. 2010 Growth: 21 % Operating margin: 10.6 % 13
Slide 14: Financial report Q1, 2011 in summary
Financial report Q1, 2011 in summary Strong start to the year Net sales rose by 45 % to SEK 30.6 million (21.1). Operating profit was SEK 2.5 million (-4.4). Profit after tax was SEK 0.1 million (-4.7) Earnings per share were SEK 0.00 (-0.20). Cash and cash equivalents at the end of the quarter were
Slide 15: Events 2011
Events 2011 CellaVision reinforced its management team with Stefan Bengtsson as Chief Operating Officer. CellaVisions new product concept for hospital networks enters the evaluation phase – Smaller laboratories with limited resources may now digitize their samples and have the analysis performed at
Slide 16: CellaVision going forward
CellaVision going forward Hematology Business Continue global market penetration in Europe, the US and Asia, with focus on North America and Japan. Product development projects with the aim of strengthening the analyzers’ customer values through increased functionality and more possible applications
Slide 17: Shareholders
Shareholders Shareholder # shares % The share Listed at NASDAQ OMX Stiftelsen Industrifonden 3,587,257 15.0 Stockholm, Small Cap May 31, 2010. Metallica Förvaltnings AB 2,773,967 11.6 Ticker symbol: CEVI Christer Fåhraeus m bolag 2,400,000 10,1 Market Cap: ~290 MSEK More than 1,600 shareholders Livf
Slide 18: Share price development since Jan 1, 2009
Share price development since Jan 1, 2009 20 800 18 700 16 600 14 500 12 10 400 8 300 6 200 4 100 2 0 0 jan- feb- mar- apr- maj- jun- jul- aug- sep- okt- nov- dec- jan- feb- mar- apr- maj- jun- jul- aug- sep- okt- nov- dec- jan- feb- mar- apr- 09 09 09 09 09 09 09 09 09 09 09 09 10 10 10 10 10 10 10
Slide 19: For more information, please visit www.cellavision.com
For more information, please visit www.cellavision.com blog.cellavision.com App: CellAtlas 19